Rezolute Says it Gets Breakthrough Therapy Designation From US FDA for Ersodetug to Treat Hypoglycemia

MT Newswires Live

01/07

Rezolute (RZLT) said Tuesday it has received the US Food and Drug Administration's

Breakthrough Therapy designation for its ersodetug monoclonal antibody to treat hypoglycemia due to congenital hyperinsulinism.

The regulator's decision was based on the company's phase 2b trial of ersodetug in patients with congenital hyperinsulinism, which "safely" showed "significant improvements" in hypoglycemia by at least 75%, with no clinically significant hyperglycemia, Rezolute added.

The company said it intends to start its phase 3 trial for tumor hyperinsulinism this year.

Shares of the company rose 3.6% in recent Tuesday trading.

Price: 5.40, Change: +0.19, Percent Change: +3.55

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"老虎國際,美股交易,港股交易,交易美股,股票信息,股價,美股行情,美股打新,港股打新,IPO打新,購買美股,全球投資","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2501785050"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2501785050\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2501785050?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-07 23:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2501785050","market":"sg","top_or_hot":-1,"title":"Rezolute Says it Gets Breakthrough Therapy Designation From US FDA for Ersodetug to Treat Hypoglycemia","media":"MT Newswires Live","content":"<html><body><p> Rezolute (RZLT) said Tuesday it has received the US Food and Drug Administration's</p><p>Breakthrough Therapy designation for its ersodetug monoclonal antibody to treat hypoglycemia due to congenital hyperinsulinism.</p><p>The regulator's decision was based on the company's phase 2b trial of ersodetug in patients with congenital hyperinsulinism, which \"safely\" showed \"significant improvements\" in hypoglycemia by at least 75%, with no clinically significant hyperglycemia, Rezolute added.</p><p>The company said it intends to start its phase 3 trial for tumor hyperinsulinism this year.</p><p>Shares of the company rose 3.6% in recent Tuesday trading.</p><p>Price: 5.40, Change: +0.19, Percent Change: +3.55</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Rezolute Says it Gets Breakthrough Therapy Designation From US FDA for Ersodetug to Treat Hypoglycemia</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRezolute Says it Gets Breakthrough Therapy Designation From US FDA for Ersodetug to Treat Hypoglycemia\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2025-01-07 23:34</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> Rezolute (RZLT) said Tuesday it has received the US Food and Drug Administration's</p><p>Breakthrough Therapy designation for its ersodetug monoclonal antibody to treat hypoglycemia due to congenital hyperinsulinism.</p><p>The regulator's decision was based on the company's phase 2b trial of ersodetug in patients with congenital hyperinsulinism, which \"safely\" showed \"significant improvements\" in hypoglycemia by at least 75%, with no clinically significant hyperglycemia, Rezolute added.</p><p>The company said it intends to start its phase 3 trial for tumor hyperinsulinism this year.</p><p>Shares of the company rose 3.6% in recent Tuesday trading.</p><p>Price: 5.40, Change: +0.19, Percent Change: +3.55</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RZLT","symbol_name":"Rezolute, Inc.","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2501785050","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2501785050","pubTimestamp":1736264078,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Rezolute (RZLT) said Tuesday it has received the US Food and Drug Administration'sBreakthrough Therapy designation for its ersodetug monoclonal antibody to treat hypoglycemia due to congenital hyperin","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"RZLT":"Rezolute, Inc.","BK4139":"生物科技"},"translate_title":"Rezolute称Ersodetug治疗低血糖获得美国FDA突破性疗法认定","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RZLT":0.9},"content_text":"Rezolute (RZLT) said Tuesday it has received the US Food and Drug Administration'sBreakthrough Therapy designation for its ersodetug monoclonal antibody to treat hypoglycemia due to congenital hyperinsulinism.The regulator's decision was based on the company's phase 2b trial of ersodetug in patients with congenital hyperinsulinism, which \"safely\" showed \"significant improvements\" in hypoglycemia by at least 75%, with no clinically significant hyperglycemia, Rezolute added.The company said it intends to start its phase 3 trial for tumor hyperinsulinism this year.Shares of the company rose 3.6% in recent Tuesday trading.Price: 5.40, Change: +0.19, Percent Change: +3.55","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}